EP1455822A4 - Compositions lyophilisees d'anticorps monoclonaux - Google Patents

Compositions lyophilisees d'anticorps monoclonaux

Info

Publication number
EP1455822A4
EP1455822A4 EP02773798A EP02773798A EP1455822A4 EP 1455822 A4 EP1455822 A4 EP 1455822A4 EP 02773798 A EP02773798 A EP 02773798A EP 02773798 A EP02773798 A EP 02773798A EP 1455822 A4 EP1455822 A4 EP 1455822A4
Authority
EP
European Patent Office
Prior art keywords
monoclonal antibody
antibody compositions
lyophilized monoclonal
lyophilized
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02773798A
Other languages
German (de)
English (en)
Other versions
EP1455822A2 (fr
Inventor
Tracy Chen
Glen Tolman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1455822A2 publication Critical patent/EP1455822A2/fr
Publication of EP1455822A4 publication Critical patent/EP1455822A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP02773798A 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux Withdrawn EP1455822A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09
US342063P 2001-11-09
PCT/US2002/033272 WO2003041637A2 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux

Publications (2)

Publication Number Publication Date
EP1455822A2 EP1455822A2 (fr) 2004-09-15
EP1455822A4 true EP1455822A4 (fr) 2004-12-29

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02773798A Withdrawn EP1455822A4 (fr) 2001-11-09 2002-10-18 Compositions lyophilisees d'anticorps monoclonaux

Country Status (7)

Country Link
EP (1) EP1455822A4 (fr)
JP (1) JP2005508992A (fr)
AR (1) AR037304A1 (fr)
CA (1) CA2466641A1 (fr)
MX (1) MXPA04004459A (fr)
TW (1) TW200303213A (fr)
WO (1) WO2003041637A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
WO2012028683A1 (fr) 2010-09-02 2012-03-08 Novartis Ag Système de gel d'anticorps pour administration de médicament prolongée
EP4116325A1 (fr) 2010-11-05 2023-01-11 Novartis AG Procédés de traitement de la polyarthrite rhumatoïde au moyen d'antagonistes d'il-17
MA50239A (fr) 2017-09-15 2020-07-22 Amgen Inc Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987000196A1 (fr) * 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection des proteines et similaires
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
MX9709716A (es) * 1995-06-07 1998-03-31 Quadrant Holdings Cambridge Metodos para incorporar substancias estables dentro de matrices de vidrio celular secas y composiciones obtenidas mediante los mismos.
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
WO2002072636A2 (fr) * 2000-12-28 2002-09-19 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000807A1 (fr) * 1991-07-03 1993-01-21 Cryolife, Inc. Procede de stabilisation de biomateriaux
WO1993014191A1 (fr) * 1992-01-21 1993-07-22 Cryopharm Corporation Procede de congelation de cellules et de matieres analogues a des cellules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARPENTER JOHN F ET AL: "Rational design of stable lyophilized protein formulations: Some practical advice", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 14, no. 8, 1997, pages 969 - 975, XP002303280, ISSN: 0724-8741 *
GARZON-RODRIGUEZ W ET AL: "Use of polymer/sugar mixtures to optimize storage stability of freeze-dried recombinant human interleukin-11", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 221, no. 1-2, April 2001 (2001-04-01), & 221ST NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY; SAN DIEGO, CALIFORNIA, USA; APRIL 01-05, 2001, pages BIOT 14, XP009039111, ISSN: 0065-7727 *
SEARLES JAMES A ET AL: "Annealing to optimize the primary drying rate, reduce freezing-induced drying rate heterogeneity, and determine Tg' in pharmaceutical lyophilization", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 90, no. 7, July 2001 (2001-07-01), pages 872 - 887, XP002303281, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
JP2005508992A (ja) 2005-04-07
TW200303213A (en) 2003-09-01
MXPA04004459A (es) 2005-05-16
CA2466641A1 (fr) 2003-05-22
AR037304A1 (es) 2004-11-03
EP1455822A2 (fr) 2004-09-15
WO2003041637A2 (fr) 2003-05-22
WO2003041637A3 (fr) 2004-01-22

Similar Documents

Publication Publication Date Title
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
EP1391464A4 (fr) Anticorps monoclonal anti-cd40
EP1432444A4 (fr) Anticorps anti-a beta
HK1074206A1 (en) Anti-trail-r antibodies
HUP0402333A3 (en) Modified anti-tnf alpha antibody
IL166244A0 (en) Super humanized antibodies
IL156030A0 (en) Humanized antibodies
AU2002251562A1 (en) Anti-CD40 monoclonal antibody
AU1174702A (en) Humanized anti-lt-beta-r antibodies
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
PL354112A1 (en) Application of anti-ctla-4 antibodies
AU2002365649A8 (en) Anti-dota antibody
GB0126378D0 (en) Antigen
AU2002359495A8 (en) Anti-tnf antibodies, compositions, methods and uses
AUPR546801A0 (en) Recombinant antibodies
EP1633399A4 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
AU2002365269A8 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
EP1455822A4 (fr) Compositions lyophilisees d'anticorps monoclonaux
EP1393746A4 (fr) Compositions d'anticorps polyclonaux humains
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
PL374269A1 (en) Kgf polypeptide compositions
EP1446416A4 (fr) Anticorps monoclonaux specifiques de tumeur
GB0121727D0 (en) Monoclonal antibodies
GB0031284D0 (en) High affinity antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040608

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041116

17Q First examination report despatched

Effective date: 20060927

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070208